Exicure (XCUR) Return on Capital Employed (2017 - 2026)
Exicure's (XCUR) quarterly Return on Capital Employed came in at 98.41% in Q1 2026, down 3780.0% YoY from 2.67% in Q1 2025, and down 150.29% on a QoQ basis from 39.32% in Q4 2025.
Exicure (XCUR) Return on Capital Employed (2017 - 2026) Analysis & Trends
Exicure (XCUR) has 10 years of Return on Capital Employed data on file, last reported at 98.41% in Q1 2026.
- Quarterly Return on Capital Employed fell 3780.0% year-over-year to 98.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.41% (down 3780.0% YoY) and the FY2025 annual result came in at 39.71%, up 7966.0% from the prior year.
- Return on Capital Employed retreated to 98.41% in Q1 2026, from 39.32% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 39.11% in Q3 2023 to a low of 467.97% in Q3 2022.
- A 5-year average of 104.75% and a median of 87.67% in 2024 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 35440 bps — and 2023, when it jumped 50708 bps.
- Tracing XCUR's Return on Capital Employed over 5 years: stood at 7.47% in 2022, then tumbled by 1957 bps to 153.73% in 2023, then climbed by 19 bps to 125.17% in 2024, then jumped by 69 bps to 39.32% in 2025, then slumped by 150 bps to 98.41% in 2026.
- The last three Return on Capital Employed figures came in at 98.41% (Q1 2026), 39.32% (Q4 2025), and 67.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Exicure | 7.27 Mn | 7.27 Mn | - | -92.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.41% |
| Dec 31, 2025 | -39.32% |
| Sep 30, 2025 | -67.21% |
| Jun 30, 2025 | -64.38% |
| Mar 31, 2025 | -60.61% |
| Dec 31, 2024 | -125.17% |
| Sep 30, 2024 | -87.67% |
| Jun 30, 2024 | -94.74% |
| Mar 31, 2024 | -133.10% |
| Dec 31, 2023 | -153.73% |
| Sep 30, 2023 | 39.11% |
| Jun 30, 2023 | 16.61% |
| Mar 31, 2023 | 6.54% |
| Dec 31, 2022 | -7.47% |
| Sep 30, 2022 | -467.97% |
| Jun 30, 2022 | -261.77% |
| Mar 31, 2022 | -181.53% |
| Dec 31, 2021 | -167.62% |
| Sep 30, 2021 | -113.57% |
| Jun 30, 2021 | -69.53% |